Trial intelligence / Profile preview

AIR001 intermediate/long-term safety and efficacy extension study in WHO Group 1 pulmonary arterial hypertension

2012-000153-31Phase 2Terminated

Sponsor
Aires Pharmaceuticals, Inc.
Start
Nov 2012
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, open-label trial of inhaled nitrite in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Aires Pharmaceuticals, Inc. Primary endpoint: Intermediate/long-term safety. Started Nov 2012; status: terminated.

02

Drugs

inhaled nitrite
03

Conditions

pulmonary arterial hypertension (PAH)

Beyond the preview

Go deeper on 2012-000153-31.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-000153-31.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call